PASG - Passage Bio on go with its lead gene therapy in early-stage study nerve cell cancer in the U.K

The U.K regulatory authority has signed off Passage Bio's (PASG) trial application for global Phase 1/2 study evaluating the company's lead gene therapy, PBGM01, for the treatment of GM1 gangliosidosis (GM1). This is the first regulatory authorization for the global PBGM01 trial program, Imagine-1.The company expects to initiate dosing in Q1 of 2021. Patient enrollment for the UK clinical study site, which is part of the global program, is expected to start Q2 of 2021.In October, the company received Orphan Drug status in Europe for PBGM01 for the same indication.

For further details see:

Passage Bio on go with its lead gene therapy in early-stage study nerve cell cancer, in the U.K